Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Scientists compared high-intensity statins rosuvastatin and atorvastatin, and found both are broadly safe and effective at ...

Navigating the complex world of prescription drug pricing can feel overwhelming, particularly with the ever-increasing costs ...

The seven-year MS-STAT study, which involved almost 1,000 patients over 31 sites across the UK, concluded that simvastatin is ...

A common drug taken by millions of people in the UK has been linked to an increased risk of diabetes. Statins are taken for a ...

Atherosclerosis is the build-up of plaque in the arteries which causes their narrowing. It is a primary cause of ischemic ...

A group at NUS Yong Loo Lin School of Medicine (NUS Medicine) has created a nanoparticle technology that provides an efficient and non-invasive way to identify and treat atherosclerosis, according to ...

NUS Medicine researchers unveil breakthrough nanoparticle technology for atherosclerosis diagnosis and treatment Singapore ...

Pitavastatin is a novel statin that induces plaque regression and is non-inferior to atorvastatin and, on some measures, superior to simvastatin and to pravastatin in the elderly. Pitavastatin ...